Acera Surgical

Acera Surgical is a private medical device company pioneering electrospun nanofiber technology for soft tissue repair and regenerative medicine. Its flagship product, Restrata, is the first fully synthetic electrospun fiber matrix indicated for wound management, supported by Level I clinical evidence. The company was recently acquired by Solventum (spun off from 3M), providing significant commercial and strategic resources. Acera's platform offers a unique, animal-free alternative to traditional biologic scaffolds, targeting a broad range of surgical and chronic wound applications.

Proprietary electrospinning process creating sub-cellular, synthetic nanofibers engineered to mimic human extracellular matrix (ECM). The platform produces 100% synthetic, resorbable, enzymatically-resistant scaffolds that guide tissue repair through structural cues.

Acera competes in the advanced wound care and surgical mesh markets against large players like Integra LifeSciences, Organogenesis, Baxter, and BD, who offer biologic (porcine, bovine, human tissue-derived) and other synthetic scaffolds. Its key differentiator is its 100% synthetic, electrospun nanofiber structure that mimics native ECM, offering consistency, no immunogenic risk, and strong clinical data.